Bayer Expert Monday Series 2025

Join Us for the Bayer Expert Monday Series!

Attention Innovators and Early Stage Entrepreneurs! Do you have disruptive science but struggle to bring it to life in the entrepreneurial world? Bayer's passion is to enable and support standout healthcare innovation!

Bayer is excited to launch the 2025 Bayer Expert Monday series, designed specifically for innovative minds in the life sciences. This virtual series will provide you with exclusive access to Bayer experts who will share their invaluable insights, experiences, and guidance to help you navigate the complexities of pharmaceutical development.

Over the last two years, Bayer's Expert Mondays brought together over 5,000 innovators across 23 sessions. Let's build on this success and continue to bring breakthrough innovation to patients.

What to Expect:

Expert Insights: Each session will feature a leading expert from Bayer, covering a range of topics including drug discovery, regulatory pathways, clinical trials, and commercialization strategies, with a focus on our strategic areas of interest: oncology, cell and gene therapy, cardiovascular/renal, and immunology.
Interactive Q&A: Engage directly with our experts during live Q&A sessions, allowing you to ask your most pressing questions and gain tailored advice for your entrepreneurial journey.
Networking Opportunities: Connect with fellow early stage entrepreneurs and build valuable relationships within the pharmaceutical community.

What you need to know:

Each one-hour Bayer's Expert Monday includes a live Q&A with respective Bayer Experts.
These sessions are not intended for service providers, consultants, IT providers, etc. They are designed for drug developers and healthcare researchers seeking collaboration with big pharma and out-licensing opportunities later in their journey.
Session recordings are NOT distributed afterward. Live attendance is necessary to get the most out of the expert sessions and network with the Bayer Pharma team.
Each session has a maximum capacity of 500 participants.